A Phase 1 interventional study of IN-R00002 and IN-G00002 in Non-valvular Atrial Fibrillation (NVAF), sponsored by HK inno.N Corporation. Active, not recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-10.
Sponsored by HK inno.N Corporation · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 209 studies in Atrial Fibrillation with a site in Korea, Republic of — 61 open to participants now, 69 under way, 2 of them phase 3. Atrial Fibrillation · Korea, Republic of.
Among the 209 studies in Atrial Fibrillation with a site in Korea, Republic of, this one is the 117th largest by planned enrollment of the 144 interventional ones that give a count, is one of 12 that started in 2024, is one of 2 in phase 1, reaches primary completion later than 2 of the 68 other live ones, and was the 165th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 963 are open to participants now.
Browse Atrial Fibrillation studies →61 of the 209 studies in Atrial Fibrillation with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Inha University Hospital · Sites in Korea, Republic of
Ages 19+
Oslo University Hospital · Sites in Korea, Republic of, United States, Belgium and 7 more countries
Ages 18+
Chonnam National University Hospital · Sites in Korea, Republic of
Ages 19+
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
Yonsei University · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 609 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 19 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
209 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 22 · Phase 4 22
First in 2005; this study’s year is marked. 12 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 150 across 2,479 interventional studies indexed under Atrial Fibrillation.
Median enrollment 300 across the 144 interventional studies, 1,181 across the 65 observational. Of the 101 that completed or were terminated, 33 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
60 of 209 have an industry lead sponsor. The 10 most frequent:
HK inno.N Corporation is the lead sponsor of 104 studies on the registry; 19 are open to participants now.
HK inno.N Corporation has 1 study filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
11 of the studies in Atrial Fibrillation with a site in Korea, Republic of that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT07641582Seoul St. Mary's HospitalPrediction of Atrial Fibrillation Using Polygenic Risk Score | 2026-12-30 |
| NCT05507749Seoul National University HospitalCyroablation for Pulmonary Vein Isolation Alone in Patients With Early Persistent AF Assessed by Continuous Monitoring | 2026-12-31 |
| NCT07947498Chungnam National University HospitalPrognostic Value of 2-Week ECG Monitoring After PCI in Acute Myocardial Infarction | 2026-12-31 |
| NCT05794386Seoul National University HospitalSCAR Burden of Left Atrium Guided cathEter Ablation sTrategy for Persistent Atrial Fibrillation | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 209 studies in Atrial Fibrillation with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To compare the pharmacokinetics and safety after a single dose administration of IN-G00002 and IN-R00002 in healthy adult volunteers
A randomized, open-label, single-dose, crossover study
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
R-\>T R: IN-R00002 T: IN-G00002
Drug: IN-R00002 · Drug: IN-G00002
T-\>R R: IN-R00002 T: IN-G00002
Drug: IN-R00002 · Drug: IN-G00002
Single administration of IN-R00002 60mg
Single administration of IN-G00002 60mg
PK parameter
AUClast of Edoxaban
Time frame: Up to Day 2
PK parameter
Cmax of Edoxaban
Time frame: Up to Day 2
Ran from Aug 2024 to primary completion in Oct 2024, 1 month.
Of 20 phase 1 interventional studies under Atrial Fibrillation, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's 1 month is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.